Overcoming immune resistance in cancer
Coherus Oncology (formerly Coherus Biosciences) is a fully integrated commercial-stage biopharmaceutical company focused on developing and commercializing next-generation immuno-oncology therapies. Its approved product LOQTORZI (toripalimab-tpzi) is a PD-1 inhibitor for hard-to-treat cancers. The company's pipeline includes multiple clinical-stage candidates targeting the tumor microenvironment, including CCR8 and IL-27 pathways, with the goal of extending patient survival across tumor types.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2026
Jan 2023
Jan 2022
Apr 2020
May 2014
Jan 2014
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Global biosimulation software and services company accelerating drug development for 2,000+ bioph...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
